FOI_7418

Internal Reference Number: FOI_7418

Date Request Received: 08/09/2023 00:00:00

Date Request Replied To: 02/10/2023 00:00:00

This response was sent via: By Email

Request Summary: Immunomodulatory medications

Request Category: Researcher


Question Number 1: How many patients has your trust/health board treated in the past 6 months (for any disease) with the following drugs: • Aubagio (teriflunomide) • Avonex (interferon beta-1a) • Betaferon (interferon beta-1b) • Brabio (glatiramer acetate) • Copaxone (glatiramer acetate) • Extavia (beta interferon-1b) • Gilenya (fingolimod) • Lemtrada (alemtuzumab) • Kesimpta (ofatumumab) • Mavenclad (cladribine) • Mayzent (siponimod) • Ocrevus (ocrelizumab) • Plegridy (peginterferon beta-1a) • Ponvory (ponesimod) • Rebif (beta interferon-1a) • Tecfidera (dimethyl fumarate) • Tysabri (natalizumab) • Tysabri (natalizumab) pre-filled syringes ONLY • Vumerity (diroximel fumarate) • Zeposia (ozanimod)

Answer To Question 1: The Trust has not issued any of the drugs listed below to any patients over the past 6 months.

To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.